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Background: Secondary prevention is important for reducing both mortality and morbidity of patients with
coronary heart disease (CHD). Pharmacists can provide medication and also work on disease management for
patients with CHD. This review has been carried out to evaluate the role of pharmacist care on mortality, morbidity,
and the CHD management.
Methods: The PubMed, MEDLINE, EMBASE, Web of Science and Cochrane Central Register of Controlled Trials
databases were searched for randomized controlled trials (RCTs) to evaluate the impact of pharmacist care
interventions on patients with CHD (in both community and hospital settings). Primary outcomes of interest were
mortality, cardiovascular events and hospitalizations. Secondary outcomes were medication adherence, blood
pressure control, and lipid management.
Results: Five RCTs (2568 patients) were identified. The outcomes were mortality, cardiovascular events, and
hospitalizations in one study (421 patients), medication adherence in five studies, blood pressure in two studies
(1914 patients), and lipid management in three studies (932 patients). The interventions of pharmacists included
patient education, medication management, feedback to health care professionals, and disease management. There
was no significant effect of pharmacist care on mortality, recurrent cardiac events or hospitalization of CHD
patients. Significant positive effects of pharmacist care were shown on medication adherence in three studies, on
blood pressure control in one study and on lipid management in one study.
Conclusion: In this study, we concluded that pharmacists have a beneficial role in the care of CHD patients,
although the evidence supporting positive impacts on mortality and morbidity remains uncertain due to the
unavailability of data in these areas. Further research is needed to discern the contribution of pharmacist care on
hard endpoints of CHD.
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Coronary heart disease (CHD) is one of the leading
causes of morbidity and mortality in the world [1]. With
reference to increased survival rates after acute myocar-
dial infarction and also due to an increase of the aging
population, the burden of CHD increases gradually [1].
Secondary prevention is important because cardiovascu-
lar events occur at a high rate after an acute vascular* Correspondence: xuhuiminze@126.com
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reproduction in any medium, provided the orevent [2]. For example, about one fifth of patients were
rehospitalized for ischemic heart disease or died within a
year after the first acute coronary syndrome (ACS) [3].
Randomized studies have demonstrated the efficacy of
lifestyle changes (e.g. smoking cessation, physical activity),
and the use of medications such as aspirin, β-blockers,
angiotensin-converting enzyme (ACE) inhibitors and sta-
tins to reduce death, reinfarction, or stroke in patients
with CHD [4,5]. The nonadherence to medications for
secondary prevention of CHD is associated with an in-
creased risk of subsequent cardiovascular events and mor-
tality [6-10]. Physicians and healthcare providers should. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Flow diagram for identification, inclusion and
exclusion of studies.
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ticipation in prescribed medical regimens and lifestyle
changes to improve the prognosis of CHD.
Pharmacists, in addition to medication dispensing, can
provide medication education and disease management
for patients, to improve medication adherence to achieve
the goals of desired therapeutic outcomes, and to improve
safe medication use. Previous systematic reviews have
demonstrated that interventions provided by pharmacists
are beneficial in the management of major cardiovascular
disease (CVD) risk factors in outpatients (e.g. lowering
blood pressure and cholesterol levels or smoking cessa-
tion) [11], and in reducing the risk of hospitalizations in
patients with heart failure [12]. The contributions from
pharmacists in CHD secondary prevention have not been
systematically reviewed so far, and hence we have carried
out this study to evaluate the role of pharmacist care on
mortality, morbidity, and the management of CHD.
Methods
Data sources and searches
A systematic literature search for randomized controlled
trials (RCTs) on MEDLINE, PubMed EMBASE, Web of
Science, and the Cochrane Central Register of Con-
trolled Trials, from their inception until July 2012 was
conducted (with an update performed in September
2013). Language restrictions were not applied. Search
terms were pharmacy-related terms (‘pharmacist’ OR
‘pharmaceutical care’ OR ‘pharmaceutical services’ OR
‘pharmacy services’ OR ‘hospital pharmacy’ OR ‘commu-
nity pharmacy’ OR ‘pharmacy’) AND CHD-related terms
(‘coronary heart disease (CHD)’ OR ‘coronary disease’
OR ‘myocardial infarction (MI)’ OR ‘angina pectoris’ OR
‘revascularization’ OR ‘coronary artery bypass grafting
(CABG)’ OR ‘percutaneous transluminal coronary angio-
plasty (PTCA)’ OR ‘percutaneous coronary intervention
(PCI)’ OR ‘coronary artery stenting’) AND trial-related
terms (‘randomized controlled trial (RCT)’ OR ‘clinical
trial’ OR ‘comparative study’). Additionally, the bibliog-
raphies of all relevant articles were reviewed.
Study selection
Two authors (HX and HC) independently screened the
citations from the literature search to determine eligibil-
ity (Figure 1). Studies were included if they (1) had a
randomized control design; (2) evaluated the impact of
pharmacist care on patients with CHD (compared with
usual care); and (3) had at least one of the outcomes of
interest. Usual care for CHD involved routine care per-
formed by a nurse, physician, and dispensing pharmacist.
Pharmacist care in this study refers to enhanced pharma-
cist care provided by a clinical pharmacist, hospital
pharmacist, community pharmacist, or pharmacy pharma-
cist. This study involves both pharmacist-directed careand pharmacist collaborative care. Primary outcomes of
interest for this study were mortality, cardiovascular
events and hospitalizations. Mortality included both car-
diovascular and non-cardiovascular mortality. Cardiovas-
cular events included non-fatal myocardial infarction,
stroke, and coronary and carotid revascularization. Hospi-
talizations referred to the total number of cardiac-related
or any-cause hospital admissions in the follow-up period.
Secondary outcomes were medication adherence, blood
pressure control, and lipid management.
Publications were excluded if they were not random-
ized, did not have adequate description of the pharma-
cist's intervention, did not directly apply to patients with
CHD, were not conducted on patients all with CHD, or
if they did not report the targeted outcomes. Disagree-
ments were resolved by discussion.
Data extraction and risk of bias assessment
Data extraction was independently performed by 2 au-
thors (HX and YH) using a standardized data extraction
form. Details about study design, participants, interven-
tions, outcomes, risk of bias data and results were ex-
tracted. Risk of bias tools were applied as described in
the Cochrane Handbook for Systematic Reviews of Inter-
vention [13]. Factors that were considered included the
following: the quality of random sequence generation and
allocation concealment (selection bias), blinding of partici-
pants and personnel (performance bias), blinding of out-
come assessment (detection bias), incomplete outcome
Cai et al. BMC Health Services Research 2013, 13:461 Page 3 of 7
http://www.biomedcentral.com/1472-6963/13/461data (attrition bias), selective reporting (reporting bias)
and other bias (e.g. extreme baseline imbalance, fraudu-
lence etc.). For each item, the quality characteristics of
each study were rated as (1) low risk of bias; (2) unclear;
and (3) high risk of bias.
Results
Searches of the electronic databases identified 480 po-
tential citations. After initial screening of titles and ab-
stracts, 130 full-text studies were assessed for eligibility
and five RCTs [14-18], all published in the English lan-
guage, met the inclusion criteria. Figure 1 provides infor-
mation on the number of studies identified, included
and excluded, and the reasons for exclusion.
Description of studies and types of interventions
Table 1 summarizes the characteristics of the included
studies [14-18]. Overall, five studies involving a total of
2568 participants compared pharmacist interventions
with usual care. Four studies were conducted in the
United States (US) [14,16-18], and one in England [15].
The outcomes were mortality, cardiovascular events, and
hospitalizations in one study (421 patients) [17], medica-
tion adherence in five studies [14-16,18], blood pressure
in two studies (1914 patients) [15,17], and lipid manage-
ment in three studies (932 patients) [16-18]. Three
studies were conducted in hospital, outpatients clinics,
or medical offices [16-18]; one study was conducted in
community pharmacies [15]; and one in both hospital
and community pharmacies [14]. One cluster RCT was
randomized at clinic [18], and the remaining four trials
were randomized at a patient level [14-17].
The interventions delivered by pharmacists included
(1) patient education (defined as education or counseling
about therapy, medication compliance, lifestyle, social
support etc.) in five studies [14-18]; (2) medication man-
agement (defined as medication review from medical re-
cords or patient interview; providing tools to improve
medication compliance; assessment of medication com-
pliance; monitoring of medication therapy such as as-
sessment, adjustment, change of medications etc.) in five
studies [14-18]; (3) feedback to health care professionals
in three studies [14,15,18]; and (4) disease management
(defined as assessment of targets for medication therapy
such as blood pressure and lipid, and lifestyle such as
smoking, obesity etc.) in four studies [15-18].
Methodological quality of included studies
The studies were of variable methodological quality. Three
studies provided evidence of adequate random sequence
generation [14,16,17] and only two studies reported ad-
equate concealment [14,15]. Because of the nature of the
interventions, none of the studies blinded study partici-
pants to the pharmacist intervention, but two studiesprovided evidence of blinding assessment of outcome data
[14,15]. High risks of bias existed in selection, perform-
ance and detection in the cluster RCT study [18].
Primary outcomes
Mortality, cardiac events, and hospitalizations
Only one study reported all-cause mortality, the occur-
rence of fatal/nonfatal coronary events (acute MI, PCI,
and CABG), and any-cause hospitalization as a second-
ary outcome of that study [17]. The study demonstrated
that there was no difference in all-cause mortality, coron-
ary events, or any-cause hospitalization between pharma-
cist care and the control group.
Secondary outcomes
Medication adherence
All the five studies reported about medication adherence.
Methods of medication adherence assessment and main
outcomes of each study are shown in Table 2. Medication
adherence was assessed by prescription in five studies
[14,16-18], by patient self-reported in two studies [14,15],
and by pill and package count in one study [16]. Adher-
ence to aspirin and β-blocker were reported in two studies
[14,15], lipid-lowering drug in five studies [14-18], and an
ACE inhibitor in one study [15]. None of the studies
demonstrated a statistically significant difference between
pharmacist care and control in adherence to aspirin and
an ACE inhibitor. Medication adherence was significantly
increased in the intervention group than in the control
group, for a β-blocker in one study [14], and for lipid-
lowering drug in two studies [16,18].
Blood pressure (BP) control
Two studies reported the number of patients who
achieved BP control target values [15,17]. One study
demonstrated a statistically significant increase in BP
control rate for pharmacist care compared with control
[17] (Table 3).
Lipid management
Three studies reported the number of patients who
achieved low-density lipoprotein cholesterol (LDL-C) con-
trol target levels [16-18]. Two studies demonstrated a sta-
tistically significant increase in LDL-C control rate for
pharmacist care compared with control [16,18] (Table 3).
Two studies reported changes in lipid profiles in ac-
cordance with certain previous studies [16,18] and both
of these studies reported a greater reduction in LDL-C
levels with pharmacist care compared to controls.
Discussion
Our systematic review, identified five RCTs (2568 pa-
tients) assessing the effects of pharmacist care in the
secondary prevention of CHD. The ‘dose’, ‘duration’,
Table 1 Characteristics of included studies

























prior PTCA or CABG);
62 years
Focused medication
counseling performed by the
hospital study pharmacist,
who identified and addressed
barriers to medication
adherence. A pocket
medication card, a list of tips
for remembering to take








back to the patient and the
patient’s care team























lifestyle and social support
were provided by the
community pharmacist and
recommendations were
recorded and sent to the GP,
who returned annotated










Outpatient clinic RCT, 2 years 30 (15/15) Patients 7 ~ 30 days
after PTCA or CABG
and baseline fasting
LDL-C >130 mg/dl
(3.3 mmol/L); 63 years
Pharmacist telephoned
patients, emphasized on the
importance of therapy, asked
patients about when and
where prescriptions were
filled, how they paid for their
prescriptions, potential side
effects, overall well-being,













Medical offices RCT, 2 years 421 (214/207) CAD patients (AMI,
CABG, PCI) who had
been enrolled in the
CPCRS for at least





Review of laboratory results,
blood pressure, medications
and adherence, counseling
on diet and exercise
regimens, making medication
adjustments, ordering follow-
up laboratory tests, and mail-
ing laboratory reminder let-
ters for patients






























Table 1 Characteristics of included studies (Continued)
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Abbreviations: AMI acute myocardial infarction, BP blood pressure, CABG coronary artery bypass graft, CAD coronary artery disease, CHD coronary heart disease, CPCRS Clinical Pharmacy Cardiac Risk Service, GP general
practitioner, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, MEDMAN Medicines Management, PCI percutaneous coronary intervention, PTCA percutaneous transluminal coronary




















Table 2 Summary of medication adherence measures in included studies
Source Method of measuring
adherence
Medication involved Outcome




No significant difference in self-reported
adherence
Better adherence to β-blocker in prescription
assessed adherence in intervention than in
control (P = 0.03)
The MEDMAN study [15],
2007
Patient self-report Aspirin, lipid-lowering drug,
β-blocker, and ACE inhibitor
No significant difference
Faulkner [16], 2000 Pill counts at 6 and 12 weeks and
prescription records assessment
at 1 and 2 years
Lipid-lowering drug No significant difference at 6 or 12 weeks
Medication compliance was significantly
higher in intervention than in control (P < 0.05)
Olson [17], 2009 Prescription records assessment Lipid-lowering drug No significant difference
Straka [18], 2005 Prescription records assessment Lipid-lowering drug Medication compliance was higher in intervention
than in control (78% versus 44.1%)
Abbreviations: ACE angiotensin-converting enzyme.
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across the studies. Our study did not show any survival
benefits, or reduction in cardiac events and hospitaliza-
tions from pharmacist care in patients with CHD. How-
ever, it shows that the pharmacist can help to improve
medication adherence, blood pressure and lipid control.
This review did not confirm the benefits of pharmacist
intervention on mortality and morbidity of CHD. There
are two possible explanations. First, as there are only a few
trials available, with insufficient numbers of participants,
there may not be adequate statistical power to detect clin-
ical differences. Only one study used ‘hard endpoints’
(such as mortality, cardiac events and hospitalizations) as
secondary outcomes of the study, and the sample size was
not estimated based on these [17]. Second, the design of
this study was quite different from the others, where all of
the patients received a disease management program from
a clinical pharmacy specialist and had achieved targetTable 3 Summary of BP control and lipid management in incl
Source Target for BP or lipid management
The MEDMAN study [15], 2007 BP: < 140/85 mmHg
Faulkner [16], 2000 LDL-C: ≤ 100 mg/dL (2.6 mmol/L)
Olson [17], 2009 LDL-C and non-HDL-C: < 100 mg/dL (2.6 m
< 130 mg/dL (3.3 mmol/L) for all patients,
(1.8 mmol/L) and < 100 mg/dL (2.6 mmol/
with diabetes, multivessel coronary disease
recurrent coronary event, or current smoke
BP: < 140/90 mmHg for all patients, <130/
patients with diabetes or CKD
Straka [18], 2005 LDL-C: ≤ 100 mg/dL (2.6 mmol/L)
Abbreviations: BP blood pressure, CKD chronic kidney disease, CVD cardiovascular di
lipoprotein cholesterol.cholesterol values before randomization. The aim of this
study was to evaluate whether patients with CHD dis-
charged from the management program could maintain
their lipid profile levels. Thus, even patients in the control
group also received intensive pharmacist care before the
study. Unfortunately, we could not find any other study
comparing the pharmacist care to the ‘real’ usual care
for mortality, cardiac events and hospitalizations of pa-
tients with CHD. Further research is needed regarding
the contribution of pharmacist care on mortality and
morbidity of CHD.
Although there are no reports on the benefits of
pharmacist intervention in mortality and morbidity of
CHD, this review details the potential benefits of pharma-
cists on CHD care processes. Pharmacist care showed
positive effects on medication adherence [14,16,18], blood
pressure control [17] and lipid management [16,18]. Since
medication nonadherence is associated with an increaseduded studies
Outcome
No significant difference
No significant difference at 6 or 12 weeks
More patients achieved target in intervention than in




, at least 1
rs
No significant difference in maintaining LDL-C and
non-HDL-C goal, and BP goal of < 130 mmHg
80 mmHg for More patients maintained a BP goal of < 140 mmHg in
intervention than in control (P = 0.03)
More patients achieved LDL-C goal in intervention than
in control at 6.5 months and the following 18 months
(P < 0.001)
sease, HDL-C high-density lipoprotein cholesterol, LDL-C low-density
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[6-10], improvements in medication adherence will lead
to clinically important reductions in recurrent myocardial
infarctions and death.
Conclusion
Due to the unavailability of data and the limited number
of the studies, we could not carry out a quantitative
meta-analysis. However, through qualitative analysis of
the available data, we were able to evaluate the impact
of pharmacist care on patients with CHD. However, the
hypothesis that pharmacist care is beneficial for CHD
care, with respect to mortality and morbidity, should be
verified.
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